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Abstract 
Context: Genetic variants in SLC16A2, encoding the thyroid hormone transporter MCT8, 
can cause intellectual and motor disability and abnormal serum thyroid function tests, 
known as MCT8 deficiency. The C-terminal domain of MCT8 is poorly conserved, which 
complicates prediction of the deleteriousness of variants in this region. We studied the 
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Methods: We enrolled male subjects with intellectual disability in whom genetic variants 
were identified in exon 6 of SLC16A2. The impact of identified variants was evaluated in 
transiently transfected cell lines and patient-derived fibroblasts.
Results: Seven individuals from 5 families harbored potentially deleterious variants 
affecting the C-terminal domain of MCT8. Two boys with clinical features considered 
atypical for MCT8 deficiency had a missense variant [c.1724A>G;p.(His575Arg) or 
c.1796A>G;p.(Asn599Ser)] that did not affect MCT8 function in transfected cells or patient-
derived fibroblasts, challenging a causal relationship. Two brothers with classical MCT8 
deficiency had a truncating c.1695delT;p.(Val566*) variant that completely inactivated 
MCT8 in vitro. The 3 other boys had relatively less-severe clinical features and harbored 
frameshift variants that elongate the MCT8 protein [c.1805delT;p.(Leu602HisfsTer680) and 
c.del1826-1835;p.(Pro609GlnfsTer676)] and retained ~50% residual activity. Additional 
truncating variants within transmembrane domain 12 were fully inactivating, whereas 
those within the intracellular C-terminal tail were tolerated.
Conclusions: Variants affecting the intracellular C-terminal tail of MCT8 are likely benign 
unless they cause frameshifts that elongate the MCT8 protein. These findings provide 
clinical guidance in the assessment of the pathogenicity of variants within the C-terminal 
domain of MCT8.
Key Words:  monocarboxylate transporter 8, MCT8, Allan-Herndon-Dudley syndrome, AHDS, MCT8 deficiency, thy-
roid hormone transport
Thyroid hormone requires transporter proteins to facilitate its 
transport across the cell membrane (1, 2). Monocarboxylate 
transporter (MCT)8 is the most specific thyroid hormone 
transporter identified to date and facilitates the cellular up-
take and efflux of 3,3′,5-triiodothyronine (T3) and thyroxine 
(T4) (3, 4). Genetic variants in the SLC16A2 gene, encoding 
MCT8, may result in MCT8 deficiency (Allan-Herndon-
Dudley syndrome, AHDS, OMIM 300523)  characterized 
by severe intellectual and motor disability and abnormal 
thyroid function tests (increased serum T3, reduced T4, and 
high-normal thyrotropin [TSH] concentrations) (5, 6). The 
profound neurocognitive phenotype has been attributed to 
impaired transport of thyroid hormone across the blood-
brain barrier and into target cells in the brain (7, 8). Tissues 
that rely on transporters other than MCT8 are exposed to 
high serum T3 concentrations, resulting in classical signs of 
tissue thyrotoxicosis, such as impaired weight gain, tachy-
cardia, and increased perspiration.
Over the last decade, there have been many reports of pa-
tients with MCT8 deficiency who harbor different underlying 
pathogenic variants in SLC16A2 (reviewed in (2, 9)). The 
majority of affected individuals exhibit severe intellectual dis-
ability, have poor head control, are unable to sit independ-
ently, and are nonverbal. However, some individuals are able 
to walk and talk in simple sentences (eg, (10)). Not all vari-
ants in SLC16A2 cause MCT8 deficiency, which may lead 
to misinterpretation of causality and diagnostic delay. Given 
the increased application of next-generation sequencing tech-
niques in clinical practice, there is a growing need for tools 
that accurately differentiate disease causing variants from rare 
variants that have no impact on MCT8 function (11). For 
this purpose, in silico prediction tools, based on genetic con-
servation, are often used (eg, (12-15)). However, such tools 
frequently yield inconclusive results, especially when variants 
affect poorly conserved regions. This warrants complemen-
tary approaches to prove causality. Ideally this entails func-
tional evaluation of the variant in overexpression models or 
patient-derived cells. Although these systems have proven to 
provide good disease models for MCT8 deficiency (eg, (16-
18)), they are not ubiquitously available. Alternatively, know-
ledge on protein structure could help predicting the impact of 
variants on protein function, but crystal structures of MCT8 
are not yet available. Although protein homology models have 
provided important insights into the structure-function rela-
tion of, particularly, the 12 transmembrane domains (TMD) 
of MCT8 (19-21), the available models lack the entire intra-
cellular N- and C-terminal tails. The function of these do-
mains is currently unknown, although they account for ~25% 
of the protein size. Insight into their functional relevance is 
crucial for the interpretation of novel variants in these regions.
Here, we studied the functional characteristics of 5 
novel variants within the C-terminal domain of MCT8 
and examined their relation to the observed phenotype 
in boys with developmental delay. We took advantage 
of these and additional premature stop variants to de-
termine the minimal length of the C-terminal tail re-
quired for normal MCT8 function in vitro. Together, 
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pathogenicity of variants within the C-terminal domain 
of the MCT8 protein.
Methods
Study design and participants
In this case series, we have included male individuals with 
intellectual disability in whom a genetic variant within 
exon 6 of the SLC16A2 gene, encoding TMD12 and the 
intracellular C-terminal tail of MCT8, had been identified 
in the context of routine diagnostic process and for whom 
the Erasmus Medical Center fulfilled a consultancy role be-
tween January 1, 2014 and January 1, 2020.
Genetic analysis
Genetic analyses had been carried out in the context of 
routine clinical practice using exome sequencing or target 
sequencing of the SLC16A2 gene (Xq13.2) according 
to standard methods. Nucleotides and amino acid res-
idues were numbered according to the reference gene se-
quence of the transcript GenBank (NCBI) NM_006517.3 
(NP_006508.1) with the A  of the ATG translation initi-
ation codon of the long MCT8 translational isoform re-
garded as nucleotide position +1 and the corresponding 
initiation coding as the first amino acid codon (referred 
to as long isoform; widely used reference sequence in the 
available literature on MCT8 deficiency), and according 
to the reference gene sequence of the transcript GenBank 
(NCBI) NM_006517.5 (NP_006508.2) (referred to as 
short isoform; the novel official reference sequence in 
Ensembl, HGMD, and gnomAD). In silico analysis of 
pathogenicity was performed using the PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/) (14), CADD (https://
cadd.gs.washington.edu/) (13), PROVEAN (http://provean.
jcvi.org/index.php) (12), and SIFT (http://sift.jcvi.org/) (15) 
prediction tools. NMDEscPredictor was used to predict if 
frameshift variants escape nonsense-mediated decay or deg-
radation via non-stop RNA decay (https://nmdprediction.
shinyapps.io/nmdescpredictor/) (22).
Materials
Unlabeled iodothyronines, silychristin, bovine serum al-
bumin (BSA), and D-glucose were obtained from Sigma-
Aldrich (Zwijndrecht, The Netherlands [NL]). [125I]-T3 
and [125I]-T4 were prepared as previously described (23). 
X-tremeGENE9 transfection reagent was obtained from 
Roche Diagnostics (Woerden, NL). Cell culture flasks and 
plates were obtained from Corning (Schiphol, NL). An 
overview of the antibodies is provided in Supplemental 
Table 1 (24). Sulfo-NHS-biotin was obtained from Gentaur 
(Eersel, NL). Neutravidin agarose was obtained from 
Thermo Fisher Scientific (Bleiswijk, NL).
Plasmids
The cloning of wild-type (WT) human MCT8 cDNA into 
pcDNA3 and human μ-crystallin (CRYM) into pSG5 has 
been described previously (4, 25). The generation of a WT 
human MCT8 expression construct containing a 227-nu-
cleotide extension of the 3′UTR (further referred to as 
3′UTR-MCT8) has been described before (26). The indi-
cated variants were introduced using site-directed muta-
genesis according to manufacturer’s protocol (Stratagene, 
Amsterdam, NL), using primers available upon request. 
The 3′UTR-MCT8 construct was used as a template for 
all frameshift variants that resulted in an alternate reading 
frame that exceeded the natural stop codon of MCT8, 
whereas the regular MCT8 expression construct was used 
as a template for all other variants. All constructs were 
sequenced to confirm the presence of the intended variant.
Cell culture and transfection
COS-1 African green monkey kidney (CVCL_0223) and 
JEG-3 human choriocarcinoma (CVCL_0363) cells were 
obtained from ECACC (Sigma-Aldrich) and were cultured 
and transiently transfected as previously described (20). 
For T3 uptake studies, COS-1 or JEG-3 cells were cultured 
in 24-well plates, and transiently transfected at 70% con-
fluence with 100 ng pcDNA3 empty vector (EV), or 100 ng 
WT or indicated mutant MCT8 expression construct in 
the presence or absence of 50 ng CRYM. Kinetic studies 
were performed in the absence of CRYM. For surface 
biotinylation studies, cells were seeded in 6-well plates (6 
wells per condition, which were pooled during lysate prep-
aration) and transiently transfected with 500 ng pcDNA3 
EV, WT, or indicated mutant MCT8 per well. For im-
munocytochemistry, JEG-3 cells were cultured in 24-well 
dishes on 10-mm glass coverslips coated with poly-D-lysine 
(Sigma-Aldrich).
Human fibroblasts were derived from skin biopsies 
and cultured in Dulbecco’s modified Eagle medium/F12 
medium (Invitrogen, Breda, NL), containing 9% heat-
inactivated fetal bovine serum (Invitrogen), 2% penicillin/
streptomycin (Roche, Woerden, The Netherlands). For up-
take studies, fibroblasts were seeded in 6-well plates and 
grown until >95% confluence (27).
Thyroid hormone uptake studies
Thyroid hormone uptake studies were performed using 
well-established protocols (eg, (28)). Cells were washed 
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[PBS]+Ca2+/Mg2+ supplemented with 0.1% glucose and 
0.1% BSA) and incubated in incubation buffer containing 
1 nM (50 000 cpm) [125I]-T3 or [125I]-T4 for 30 minutes 
(standard uptake studies) or 10 minutes (kinetic studies). 
After indicated incubation times, cells were briefly washed 
with incubation buffer and lysed in 0.1 M sodium hy-
droxide. The internalized radioactivity was measured 
with a gamma-counter. Thyroid hormone uptake levels in 
human fibroblasts were corrected for total protein concen-
trations as measured by Bradford assay according to the 
manufacturer’s guidance (Bio-Rad, Veenendaal, NL).
Cell surface biotinylation and immunoblotting
Cell surface biotinylation studies were performed according 
to well-established protocols (20, 27). Cell surface proteins 
were labeled with Sulfo-NHS-biotin and lysed in IP buffer 
(50 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 1% Triton 
X-100), containing protease inhibitor cocktail (Roche). 
After brief sonication, samples were clarified from nuclear 
debris by centrifugation (15000g for 10 minutes). A  5% 
aliquot was used as an input control. Cell surface proteins 
were isolated using Neutravidin agarose beads (Thermo 
Fisher Scientific) and eluted in NuPAGE 1× lithium dodecyl 
sulfate loading buffer (Thermo Fisher Scientific) containing 
10 mM dithiothreitol by incubating the beads for 5 min-
utes at 90 °C prior to immunoblot analyses. Samples were 
analyzed by immunoblotting as previously described (20, 
27), using antibodies listed in Supplemental Table S1 and 
Odyssey detection methods (24). If indicated, 1  μmol of 
MG132 was added to the incubation medium 24 hours 
after transfection to inhibit proteasomal degradation.
Immunocytochemistry
Transiently transfected JEG-3 cells were fixed with 4% 
paraformaldehyde and permeabilized with 0.25% triton 
X-100 in PBS 48 hours after transfection. Samples were 
blocked for 1 hour at room temperature in PBS containing 
2% BSA (Sigma-Aldrich), and incubated overnight with rabbit 
anti-MCT8 (1:1000) and mouse monoclonal ZO-1 antibody 
(1:500), which served as a membrane marker. After secondary 
staining with goat anti-rabbit Alexa Fluor 488 (1:1000) and 
goat anti-mouse Alexa Fluor 633 (1:1000), cover slips were 
mounted on glass slides with Prolong Gold containing DAPI 
(Invitrogen) and examined as previously described (28).
Quantitative polymerase chain reaction
Total RNA was extracted from transfected JEG-3 cells cul-
tured in 12-well plates using the High Pure RNA Isolation 
Kit (Roche Diagnostics), and cDNA was produced from 
1 µg messenger RNA (mRNA) using the Transcriptor High 
Fidelity cDNA Synthesis Kit (Roche Diagnostics) according 
to the manufacturer`s protocol. Quantitative polymerase 
chain reaction was performed as previously described, 
using a probe-based assay for the detection of MCT8 and 
cyclophilin A (29). MCT8 expression levels are corrected 
for the housekeeping gene cyclophilin A and expressed as 
fold difference over 3′UTR-MCT8.
Ethical considerations
Skin fibroblasts were collected for diagnostic purposes by 
caregiving physicians. Clinical examinations were carried 
out in the context of routine care and were retrospectively 
described. Written informed consent was obtained from the 
parents or legal representatives of the involved patients to 
use their medical data for publication. This study was con-
ducted in agreement with the Medical Research Involving 
Human Subjects Act and (if applicable) formal ethics ap-
proval was obtained from the relevant institutional ethical 
committee(s).
Statistical analysis
All statistical analyses were performed using GraphPad 
Prism Version 5 software (GraphPad Software Inc., San 
Diego, USA). Transporter kinetics were determined using 
standard Michaelis-Menten equations implemented in 
GraphPad Prism. Statistically significant differences are in-
dicated as described in the figure legends.
Results
Description of individuals with classical features 
of MCT8 deficiency
Probands P1 and P2 are dizygotic twins born to 
nonconsanguineous parents. Their initial presentation 
included severe developmental delay and feeding prob-
lems, necessitating percutaneous tube feeding from the 
first year of life. At time of referral, both boys were 
7.5  years old and had not achieved any early develop-
mental milestones (Table  1). Severe truncal hypotonia 
was present, accompanied by dystonic posturing and 
brisk tendon reflexes in the limbs. Because of severe 
spastic-dystonic movement disorder, intrathecal baclofen 
treatment was started at age 11 years. Language devel-
opment was limited to some phonation. Scoliosis and 
gastric reflux disorder were present in both boys. Body 
height and weight were within low-normal range for age 
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hypertension and increased perspiration were present in 
P1. Sequential brain magnetic resonance imaging (MRI) 
showed delayed myelination in both probands. Serum 
thyroid function tests at age 7.5 years showed, like those 
at age 2 years, the characteristic pattern of MCT8 defi-
ciency, with high serum T3 concentrations and low (free) 
T4 and reverse T3 (rT3) concentrations (Table 1). In add-
ition, serum sex-hormone–binding globulin concentra-
tions were elevated and total cholesterol concentrations 
were low (Table 1).
P3 is a currently 4.5-year-old boy born to 
nonconsanguineous parents, who presented global de-
velopmental delay and failure to thrive. The presence of 
generalized hypotonia and delayed motor development 
prompted referral to the pediatric neurologist by the age of 
14 months. At that time, he was able to roll over and had 
attained head control. Brain MRI was reportedly normal. 
Electroencephalography (EEG) revealed a slow back-
ground pattern, but no epileptic activity despite the pres-
ence of staring spells. At time of last evaluation at the age 
of 4.5 years, he was able to briefly stand independently and 
understand verbal commands. He had been able to speak in 
words, but with poor articulation. This recently regressed 
to babbling. Despite his ability to maintain body posturing, 
truncal hypotonia was present. His initial growth was un-
remarkable, but at the last evaluation, he has difficulty 
gaining weight. Tachycardia was present in rest. Serum thy-
roid function tests showed the classical pattern of MCT8 
deficiency (Table 1).
P4 and his older half-brother P5 were born to 
nonconsanguineous parents and have the same biological 
mother, but different fathers. Both boys presented devel-
opmental delay with truncal hypotonia, dystonic pos-
turing, and spasticity. P5 achieved full head control at the 
age of 1  year, although he never acquired independent 
sitting. Dysmorphic features include elongated face, with 
prominent ears in both boys and pectus excavatum in P4. 
Orchidopexy was performed for treatment of retractile and 
undescended testes in P4 and P5, respectively. Body weight 
was low for age, and particularly P5 was severely under-
weight. Irritability was present in both boys. Measurement 
of thyroid hormone function tests revealed a marginally in-
creased T3, a low-normal free T4 and normal TSH in P4, 
and a marginally increased T3, low free T4 and normal 
TSH in P5 (Table 1). Notably, also serum sex hormone–
binding globulin was elevated in P5.
Description of individuals without distinctive 
features of MCT8 deficiency
P6 presented at the age of 7 years with severe intellectual dis-
ability, microcephaly, and a low body weight for age. Motor 
development was delayed. Independent sitting was achieved 
by the age of 11 months and he was able to walk independ-
ently by the age of 4 years. He was able to speak his first 
words by the age of 5 years. By the age of 8 years, he devel-
oped tonic-clonic seizures with epileptic abnormalities detect-
able on EEG. At the time of his last evaluation at the age of 
9 years and 4 months, he still exhibited mild clumsiness with 
difficulties in climbing the stairs and he could only speak 3 
to 4 words. Social interaction was normal. Body weight was 
low for age (−3.23 SD) and height was within the low-normal 
range (−1.9 SD). He did not present either marked hypotonia, 
or spasticity and dystonic features. Brain MRI performed at 
12 months and 3 years of age were normal. Thyroid func-
tion tests at the age of 7 years exhibited serum T3 concentra-
tions within normal range and (free) T4 concentrations at the 
lower end of the normal range (Table 1).
P7 presented at the age of 4 years with mild global de-
velopmental delay without additional health problems 
other than recurrent upper respiratory tract infections. 
Achievement of motor milestones and speech was delayed. 
He was 5 years at time of referral when he was able to walk 
and jump and speak in simple sentences. He reportedly had 
reduced exercise tolerance and was unable to walk for long 
distances. Mild swallowing difficulties were reported by his 
parents. He did not present hypotonia and dystonic and 
spastic features were absent, although he reportedly ex-
perienced increased muscle tone during emotional distress. 
Seizures and signs of peripheral thyrotoxicosis were absent 
(Table  1). Serum T3 concentrations were within normal 
range, whereas serum rT3 and (free) T4 concentrations 
were at the lower end of the normal range (Table 1).
Full details on probands P6 and P7 are available in the 
Supplemental Results section (24).
Genetic studies
Based on their clinical and biochemical features, DNA 
of probands P1 through P5 was tested for variants in 
SLC16A2. In P6 and P7, exome sequencing was performed 
in the context of developmental delay with unknown 
cause. The results of the sequencing analyses are graph-
ically depicted in Fig. 1A and 1B, as well as Supplemental 
Fig. S1 (24). All variants are indicated throughout the 
manuscript and figures based on the long isoform refer-
ence sequence (NM_006517.3, NP_006508.1) to facili-
tate comparison with previously published studies on 
MCT8 deficiency. A c.1695delT variant was found in P1 
and P2, resulting in a frameshift and premature trunca-
tion of the MCT8 protein at the next codon (p.(Val566*) 
[corresponding to c.1473delT;p.(Val492*) according 
to the short isoform reference sequence]. In P3, a single 
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6, resulting in a frameshift and elongation of the MCT8 
protein p.(Leu602HisfsTer680) [corresponding to 
c.1583delT;p.(Leu528HisfsTer606) according to the 
short isoform reference sequence]. In P4 and P5, a de-
letion of 10 nucleotides (c.del1826-1835) was found 
in exon 6, causing a frameshift and elongation of the 
MCT8 protein (p.(Pro609GlnfsTer676) [corresponding to 
c.del1604-1613;p.(Pro535GlnfsTer602) according to the 
short isoform reference sequence]. The unaffected mother 
was heterozygous for the same variant. All 3 frameshift 
variants were predicted to be deleterious (Table  2). The 
p.(Val566*) variant was predicted to escape nonsense-
mediated decay, whereas the p.(Leu602HisfsTer680) 
and p.(Pro609GlnfsTer676) variants might be subject 
to non-stop RNA degradation. In P6, exome sequencing 
was performed on both affected members of the family 
and their parents. A  hemizygous c.1724A>G variant 
was identified resulting in substitution of His575 by an 
Arg [p.(His575Arg) (corresponding to c.1502A>G;p.
(His501Arg) according to the short reference sequence]. 
This variant was inherited through his unaffected mother 
and has an allele frequency of 21/205358 (0.01%) al-
leles according to the gnomAD database (https://gnomad.
broadinstitute.org/; dd 04-05-2020), with 8 hemizygous 
subjects reported. Subsequent segregation sequence 
analysis also revealed the presence of this variant in a 
nonaffected maternal male cousin. Exome sequencing in 
P7 revealed a novel c.1796A>G variant, which results in 
the substitution of Asn599 by a Ser (p.(Asn599Ser) [cor-
responding to c.1574A>G;p.(Asn525Ser) according to the 
short reference sequence]. This variant was also found in 
the healthy mother and maternal grandmother and ab-
sent in 2 healthy brothers of the maternal grandmother. 
The His575 and Asn599 are both highly conserved among 
Figure 1. (A) Schematic representation of the SLC16A2 gene and MCT8 protein. The transmembrane domains (TMDs) are displayed as grey boxes 
and aligned to their coding exons. All variants identified in this study locate to exon 6 (boxed with dashed lines). (B) Schematic representation of 
TMD12 and the intracellular C-terminal tail. The locations of the identified variants are indicated, according to the reference sequence of the long 
isoform (NM_006517.3, NP_006508.1). Strongly conserved residues are colored black, whereas those with strongly similar properties across species 
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species (Supplemental Fig. S2) (24). Frequently used in 
silico prediction tools showed considerable variation in 
the predicted pathogenicity of both missense variants, re-
sulting in an initial classification as variants of unknown 
significance (Table 2).
Functional analyses of identified variants
To investigate if the identified variants in SLC16A2 were 
causative for the observed clinical phenotype, MCT8 ex-
pression constructs harboring these variants were transi-
ently overexpressed in COS-1 cells. MCT8-mediated T3 
and T4 uptake in cells expressing His575Arg or Asn599Ser 
mutant MCT8 did not significantly differ from cells ex-
pressing WT MCT8 (Fig.  2A). The Leu602HisfsTer680 
and Pro609GlnfsTer676 variants showed a ~50% reduc-
tion in T3 and T4 uptake compared with WT MCT8, 
whereas the Val566* variant was completely inactive 
(Fig.  2A and Supplemental Fig. S3A) (24). Expression 
levels of the His575Arg and Asn599Ser mutant MCT8 
proteins did not differ from WT MCT8, whereas those 
of all 3 frameshift variants were lower than WT in total 
lysates of transfected COS-1 cells (Fig.  2B). Similarly, 
the expression levels of His575Arg and Asn599Ser mu-
tant proteins at the cell membrane were equal to those 
observed for WT MCT8, whereas those of the frameshift 
variants were significantly reduced (Fig.  2C and 2D). 
Kinetic analyses of T3 transport showed that the ap-
parent Km and Vmax of the His575Arg variant did not 
differ from WT, whereas the Asn599Ser variant showed 
a marginal increase in Vmax (Fig.  2E). In contrast, the 
Leu602HisfsTer680 and Pro609GlnfsTer676 variants sig-
nificantly reduced the Vmax and Km of T3 transport by 
MCT8 (Fig.  2E). The kinetic properties of the Val566* 
mutant protein could not be studied due to the low re-
sidual uptake capacity.
In line with the observations in COS-1 cells, the 
His575Arg and Asn599Ser variants did not affect T3 
or T4 uptake in transiently transfected JEG-3 cells, 
whereas the Val566* variant was completely inactive. 
The Leu602HisfsTer680 and Pro609GlnfsTer676 vari-
ants showed T3 and T4 uptake levels amounting up to 
~20–30% of WT MCT8 (Fig.  3A and Supplemental Fig. 
S3B) (24). Immunocytochemistry performed in JEG-3 cells 
showed that the His575Arg and Asn599Ser mutant pro-
teins were predominantly localized at the cell membrane, 
as was the case for WT MCT8 (Fig. 3B). In contrast, all 
3 frameshift variants showed a pronounced perinuclear 
staining and only little expression at the cell membrane.
To further delineate if non-stop mRNA decay con-
tributes to the reduced protein expression levels of the 
Leu602HisfsTer680 and Pro609GlnfsTer676 variants in 
our in vitro model, we explored whether mRNA expres-
sion levels of both variants differed from WT MCT8 in 
transiently transfected JEG3 cells. However, mRNA ex-
pression levels of both frameshift variants were not lower 
as compared with 3′ UTR WT MCT8 (Supplemental Fig. 
S4A) (24). Alternatively, we reasoned that the lower pro-
tein expression levels of these variants could be caused by 
enhanced protein degradation. Indeed, treatment with the 
proteasome inhibitor MG132 restored protein expression 
levels of both variants toward WT levels (Supplemental Fig. 
S4B) (24).
Next, we substituted the His575 and Asn599 by an Ala 
residue to confirm that both residues are not crucial for 
MCT8 function despite their strong evolutionary conserva-
tion (Fig. 1B). Indeed, both the His575Ala and Asn599Ala 
variants facilitated the uptake of T3 and T4 to be as efficient 
as WT MCT8 in COS-1 and JEG-3 cells (Supplemental Fig. 
S5A and B) (24).
To validate the apparent benign nature of the His575Arg 
and Asn599Ser variants in an independent ex vivo model, 
we also performed T3 uptake studies in patient-derived 
fibroblasts, which have previously been shown to be a suit-
able model to study the pathogenicity of MCT8 variants 
(16). Also, in patient-derived fibroblasts, T3 uptake did not 
differ between cells harboring the His575Arg or Asn599Ser 
variant and healthy controls (Fig. 3C). In contrast, T3 uptake 
Table 2. In Silico Deleteriousness Prediction of the Identified SLC16A2 Variants
Proband Variant PROVEAN (12) CADD (13) PolyPhen2 (14) SIFT (15)
P1, P2 p.(Val566*) Deleterious (−44.7) NA NA NA
P3 p.(Leu602HisfsTer680) Deleterious (−16.3) NA NA NA
P4, P5 p.(Pro609GlnfsTer676) Deleterious (−9.0) NA NA NA
P6 p.(His575Arg) Deleterious (−3.4) Possibly deleterious (21.9) Benign (0.04) Tolerated (0.33)
P7 p.(Asn599Ser) Neutral (−1.8) Possibly deleterious (23.5) Possibly deleterious (0.21) Tolerated (0.12)
In silico prediction tools were used according to their online instructions. The following cutoffs were recommended. PROVEAN scores < -2.5 are considered dele-
terious. CADD scores >15 are generally regarded as possibly deleterious. PolyPhen-2 scores between 0.85–1.0 are considered deleterious, whereas scores between 
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Figure 2. (A) T3 and T4 uptake in transiently transfected COS-1 cells in presence of the intracellular thyroid hormone-binding protein CRYM, after 
30-minute incubation at 37 °C. Uptake levels are corrected for those observed in pcDNA3 empty vector (EV) transfected control cells and expressed 
relative to wild-type (WT) MCT8. Two-way ANOVA with Bonferroni post-tests were performed to assess for statistically significant differences be-
tween WT and indicated mutant MCT8. Data were derived from at least 3 independent repetitions in duplo. T3 and T4 uptake by WT MCT8 was not 
different from 3′UTR-MCT8 which was used to generate the Leu602HisfsTer680 and Pro609GlnfsTer676 variants and contains a 227-nucleotide exten-
sion of at 3′UTR (Supplemental Fig. S3A) (24). Immunoblot of total lysates (B) and biotinylated cell surface fraction (C) derived from COS-1 cells tran-
siently transfected with WT or indicated mutant MCT8. The total lysate comprised a 5% input samples of the clarified lysate from which the presented 
surface fraction was derived. MCT8 monomers (arrowhead) and homodimers (arrow) are indicated. (D) Quantification of the total and cell surface 
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was greatly diminished in fibroblasts derived from a previ-
ously reported patient with a Gln97ArgfsTer156 variant 
that results in premature truncation of the protein (Fig. 3C) 
(27). The MCT8-specific inhibitor silychristin (30) reduced 
T3 uptake by the His575Arg and Asn599Ser mutant fibro-
blasts and control fibroblasts to a similar extent, whereas no 
effect was observed in the Gln97ArgfsTer156 mutant fibro-
blasts (Fig. 3C). These results indicate that the His575Arg 
and Asn599Ser variants have no apparent functional conse-
quences on thyroid hormone transport in this ex vivo model.
Exploring tolerable variation in the C-terminal tail 
of MCT8
All identified variants were located in exon 6 which en-
codes TMD12 and the intracellular C-terminal tail but had 
different effects on MCT8 function. To further delineate 
the relevance of the C-terminal domain for MCT8 func-
tion, we generated a series of artificial premature stop vari-
ants that result in successive truncation of the C-terminal 
tail. Guided by our previously published MCT8 homology 
model (Fig. 4A), premature stop codons were introduced 
at positions Pro560 and Leu568 (both located within 
TMD12), His575 (located at the transition of TMD12 
and C-terminal tail), and Gly600, Pro604, and Glu610 
(all within the C-terminal tail) (Fig.  4B). All variants 
were predicted to escape nonsense-mediated decay. Upon 
overexpression in COS-1 or JEG-3 cells, the Pro560* and 
L568* variants diminished MCT8-mediated T3 and T4 
uptake, whereas all other variants had no or very limited 
effects (Fig. 4C and D). Immunoblotting on total lysates 
from transiently transfected COS-1 cells showed that the 
protein expression levels of all premature stop variants 
were lower than WT MCT8, although the difference was 
not statistically significant for the His575* and Gly600* 
variants (Fig.  4E, Supplemental Fig. S6A) (24). The cell 
surface expression levels of the Pro560* and Leu568* 
variants were about 60% lower than WT MCT8 (Fig. 4F, 
Supplemental Fig. S6A) (24). The cell surface expression 
levels of the other variants were not significantly different 
from WT. In line with the observed cell surface expression 
levels in COS-1 cells, immunocytochemistry in JEG-3 cells 
showed pronounced perinuclear staining of the Pro560* 
and Leu568* variants, whereas all other tested premature 
stop variants were predominantly expressed at the cell 
membrane (Fig. 4G and Supplemental Fig. S6B) (24).
Discussion
Here, we studied the clinical and molecular character-
istics associated with a series of variants that affect the 
C-terminal domain of the MCT8 protein. We found that 
missense variants in 2 highly conserved residues in this re-
gion, p.His575Arg and p.Asn599Ser, did not affect MCT8 
function in vitro and ex vivo, despite being predicted as 
potentially pathogenic. In line with these findings, we ob-
served that successive C-terminal truncating variants were 
generally well-tolerated until reaching the transition be-
tween the intracellular C-terminal tail and TMD12. This 
suggests that the intracellular C-terminal tail has no major 
role in MCT8 function in vitro. By contrast, elongation of 
the C-terminal tail by frameshift variants reduced MCT8 
function by interfering with proper cell membrane ex-
pression. Such variants were associated with a relatively 
less-severe clinical phenotype. Taken together, our studies 
provided important insight into the functional relevance 
and tolerable variation in the C-terminal tail of the MCT8 
protein. This can help to predict the pathogenicity of novel 
variants identified in this region.
Functional evaluation of novel variants in MCT8 is 
critical to prove causality, the importance of which is illus-
trated by the p.His575Arg (proband P6) and p.Asn599Ser 
(proband P7) variants. Although the clinical and biochem-
ical features in both individuals were deemed atypical for 
MCT8 deficiency, some frequently used in silico prediction 
tools classified both variants as potentially deleterious, 
leaving the possibility that both variants affect MCT8 
function and cause a relatively mild phenotype. Indeed, few 
variants have been associated with atypical clinical pres-
entations, including less-severe developmental delay and 
neurological manifestations, and/or serum thyroid func-
tion tests close to the normal range, as was the case for 
P6 and P7 (26, 31-33). To avoid misclassification of both 
variants and to not miss potentially mild manifestations 
of MCT8 deficiency, functional evaluation of both vari-
ants was deemed indispensable. However, neither variant 
affected MCT8 function in any of our cell-based models. 
The presence of the p.His575Arg variant in healthy male 
individuals supports the benign nature of this variant. In 
case of P7, segregation analysis was inconclusive, and alter-
native genetic diagnoses were not identified. Even though 
our models suggest that the p.Asn599Ser variant does 
not affect MCT8 function, cell-type specific effects of the 
p.Asn599Ser variant cannot be excluded. Further studies in 
displayed. Two-way ANOVA with Bonferroni post-tests were performed to assess for statistically significant differences between WT and indicated 
mutant MCT8. (E) Michaelis-Menten plots showing kinetic properties of WT and mutant MCT8 transiently expressed in COS-1 cells in the absence 
of CRYM. The uptake in cells transfected with pcDNA3 empty vector was subtracted as background. Incubations were performed for 10 minutes at 
37 °C with increasing concentrations of T3. Data are expressed as means of 3 independent experiments performed in duplo +/- SEM. Apparent Km 
and Vmax values are summarized and were compared with those obtained for WT using 1-way ANOVA with Dunnett’s post-tests. All statistically 
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patient-derived induced pluripotent stem cells (iPSc) may 
provide more robust conclusions on the pathogenicity of 
this variant.
In order to explore whether variants in the C-terminal 
tail are generally well-tolerated, we generated MCT8 
constructs with sequential C-terminal truncations. We 
found that the Pro560* and Leu568* variants were fully 
inactivating, both of which truncate the MCT8 protein 
within TMD12. Such variants likely interfere with correct 
membrane integration and may thereby disturb protein 
stability and subcellular trafficking. In line with these ob-
servations, the p.Val566* variant, identified in proband 
P1 and P2, was completely inactive and showed decreased 
cell membrane expression levels. Accordingly, both boys 
exhibited classical clinical and biochemical features of 
MCT8 deficiency present in the majority of patients with 
MCT8 deficiency (2, 9, 31). In contrast, truncations be-
yond His575, marking the transition of TMD12 to the 
Figure 3. (A) T3 and T4 uptake in transiently transfected JEG-3 cells in presence of CRYM, after 30-minute incubation at 37 °C. Uptake levels are 
corrected for those observed in pcDNA3 empty vector (EV) transfected control cells and expressed relative to WT MCT8. Two-way ANOVA with 
Bonferroni post-tests were performed to assess for statistically significant differences between WT and indicated mutant MCT8 (P < 0.005, ***). Data 
were derived from at least 3 independent repetitions in duplo. T3 and T4 uptake by WT MCT8 was not different from 3′UTR-MCT8 (Supplemental Fig. 
S3B) (24). (B) Immunocytochemistry in JEG-3 cells transiently transfected with EV, WT, or indicated mutant MCT8 using antibodies against MCT8 
(green) and the membrane marker ZO-1 (red). Cell nuclei were stained with DAPI (blue). Images are presented as an overlay image. The scale bar 
represents 20 µm. (C) T3 uptake in control and patient-derived fibroblasts in the absence (-) or presence (+) of 10 µM silychristin (SC), a potent and 
specific inhibitor of MCT8-mediated thyroid hormone transport (26). T3 uptake by control and patient-derived cells in the presence and absence of 
SC was compared using a 2-way ANOVA with Bonferroni post-tests (P < 0.001, ***; N = 2-5). The SC-induced reduction in T3 uptake did not differ 
between His575Arg and A599Ser vs control fibroblasts (1-way ANOVA with Bonferroni post hoc tests, not indicated in the graph). Amino acids are 
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Figure 4. (A) MCT8 homology model embedded in a lipid bilayer (displayed as the molecular surface, colored according to atom colors). For clarity, 
the lipid bilayer in front of the MCT8 protein is hidden. TMD12 is highlighted in green. The generation of the MCT8 homology model has been pre-
viously described (20). (B) Schematic representation of TMD12 and the intracellular C-terminal tail as shown in Fig. 1A, indicating the position of the 
truncating variants that were generated. T3 and T4 uptake in transiently transfected COS-1 (C) or JEG-3 (D) cells in presence of CRYM, after 30-minute 
incubation at 37 °C. Uptake levels are corrected for those observed in pcDNA3 empty vector (EV) transfected control cells and expressed relative to 
wild-type (WT) MCT8. Two-way ANOVA with Bonferroni post-tests were performed to assess for statistically significant differences between WT and 
indicated mutant MCT8 (P < 0.05, *; P < 0.01, **, P < 0.005 ***). Data were derived from at least 3 independent repetitions in duplicate. Representative 
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intracellular C-terminal tail, did not affect MCT8 func-
tion. Based on these findings, we postulate that truncating 
variants proximal to Leu568 likely result in complete 
loss of MCT8 function and cause severe clinical fea-
tures of MCT8 deficiency, whereas truncations beyond 
His575 likely have minimal impact on MCT8 function, 
at least in our overexpression models. Interestingly, the 
most C-terminally located missense variant reported to be 
pathogenic also affects the Leu568 residue (p.Leu568Pro) 
(32), suggesting that missense variants beyond this point 
may also be tolerated. Although systematic mutagenesis 
studies of the C-terminal domain would be necessary to 
provide definitive prove, the apparent benign nature of the 
p.His575Arg and p.Asn599Ser variants would be in line 
with this hypothesis.
Although premature truncation of the MCT8 protein be-
yond His575 was well-tolerated in vitro, elongation of the 
MCT8 protein due to frameshift variants beyond this point 
(p.Leu602HisfsTer680 and p.Pro609GlnfsTer676) reduced 
MCT8 function. In line with their modest residual activity, 
both variants were associated with a relatively less-severe clin-
ical phenotype. Affected individuals acquired several motor 
skills, including attaining head control, and P3 achieved in-
dependent standing and was able to babble. These findings 
were in line with a previous report describing a family with a 
c.1834delC frameshift variant that also elongates the MCT8 
protein [p.(Pro609LeufsTer679)]. The affected males in this 
family also displayed relatively normal thyroid function tests 
and acquired more advanced motor skills (26). Based on a 
recent large-scale phenotyping study (31), only a small pro-
portion of affected individuals exhibit relatively less-severe 
disease characteristics. Currently available data indicate that 
about 25% of patients attain head control, whereas the pro-
portion of patients acquiring more advanced motor skills 
such as independent sitting and walking is well below 10% 
(31). Interestingly, individuals with less abnormal develop-
ment also appear to exhibit less pronounced neurological 
features and might have less deranged serum thyroid func-
tion tests (eg, (31, 34, 35)). In line with these previous reports 
and in accordance with their relatively more advanced motor 
development, thyroid function tests were mildly attenuated in 
probands P3 through P5. Taken together, these observations 
suggest that frameshift mutations resulting in elongation of 
the C-terminal tail are associated with a relatively less-severe 
clinical phenotype.
Our molecular studies showed that both frame-
shift variants likely reduce protein stability and promote 
proteasomal degradation, which can, at least partly, be re-
verted by treatment with the proteasome inhibitor MG132. 
Moreover, both variants may interfere with subcellular 
trafficking, illustrated by the pronounced perinuclear lo-
calization of these mutant proteins in comparison to WT. 
We speculate that elongation of the C-terminal tail causes 
structural constraints with other intracellular domains, 
may establish novel unfavorable protein-protein inter-
actions, and/or interferes directly with substrate passage.
The function of the C-terminus is unknown. Many 
membrane proteins require ancillary protein to govern 
proper cell membrane targeting, some of which recog-
nize the C-terminal tail of their targets (36). Although 
other members of the MCT family require interactions 
with ancillary proteins for proper cell surface trans-
location (37), it is unknown if this also holds true for 
MCT8 (38). Should this be the case, such interactions 
are not likely to be established through its intracellular 
C-terminal tail as mutant proteins lacking this domain 
are fully functional and exhibited surface expression 
levels similar to WT MCT8. It should however be em-
phasized that a subset of our studies have been carried 
out in overexpressing mammalian cell lines. Factors re-
quired for optimal MCT8 expression and subcellular 
targeting may well be different in vivo and may, more-
over, vary among tissues and different cell populations 
within the same tissue. Nevertheless, overexpression 
studies in COS-1 and JEG-3 cells have been shown to 
correspond well with the in vivo MCT8 transport cap-
acity in physiologically relevant tissues. Also, MCT8 
function in patient-derived fibroblasts is typically con-
sistent with the findings in overexpression studies (eg, 
(10, 16, 27)).
Taken together, our analyses of C-terminal variants 
in MCT8 indicated that truncating variants proximal to 
Leu568 and frameshift variants that elongate the MCT8 
protein are probably damaging, whereas truncating and 
missense variants distal to His575 are likely well-tolerated 
in our cell-based disease models. These findings provide 
clinical guidance in the assessment of the pathogenicity of 
variants within the C-terminal tail of the MCT8 protein 
and underscore the relevance of validating the functional 
impact of novel variants.
MCT8 (N = 3). The total lysate comprised a 5% input samples of the clarified lysate from which the presented surface fraction was derived. MCT8 
monomers (arrowhead) and homodimers (arrow) are indicated. MCT8 (monomer) expression levels have been quantified in Supplemental Fig. S6A 
(24). (G) Immunocytochemistry in JEG-3 cells transiently transfected with indicated mutant MCT8 using antibodies against MCT8 (green) and the 
membrane marker ZO-1 (red). Cell nuclei were stained with DAPI (blue). Images are presented as an overlay image. The scale bar represents 20µm. 
Immunocytochemistry in JEG-3 cells transfected with the Gly600*, Pro604*, and Glu610* variants is shown in Supplemental Fig. S6B (24). Amino 
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